Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast
Objective. Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases that primarily affect striated muscles; skin, joints, and lungs may be involved with different degrees of severity. Traditional treatment relies on high-dose glucocorticoids and conventional synthetic disease-modifying...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-01-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/reuma/article/view/1718 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841542531730374656 |
|---|---|
| author | Chiara Rizzo Silvia Grazzini Edoardo Conticini Hector Chinoy Roberto D’Alessandro Federica Camarda Luca Cantarini Bruno Frediani Giuliana Guggino Lidia La Barbera |
| author_facet | Chiara Rizzo Silvia Grazzini Edoardo Conticini Hector Chinoy Roberto D’Alessandro Federica Camarda Luca Cantarini Bruno Frediani Giuliana Guggino Lidia La Barbera |
| author_sort | Chiara Rizzo |
| collection | DOAJ |
| description |
Objective. Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases that primarily affect striated muscles; skin, joints, and lungs may be involved with different degrees of severity. Traditional treatment relies on high-dose glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs.
Methods. A growing amount of evidence is demonstrating the potential role of novel treatments in the management of IIM. We report our experience with Janus kinase inhibitors (JAKi) in these conditions and review the current evidence for the use of small molecules in real-life clinical practice.
Results. A total of 41 papers were retrieved from PubMed, 37 papers concerning IIM and JAKi, and 4 papers concerning IIM and apremilast.
Conclusions. An overall good efficacy was evidenced in IIM-associated skin lesions, including rash, ulcers, and calcinosis. If present, muscle and joint involvement demonstrated a good response to therapy, while it was not possible to draw any conclusion about dysphagia. No life-threatening adverse events were reported.
|
| format | Article |
| id | doaj-art-2ecaf44b3b5d4be88f33bf0cc617e61b |
| institution | Kabale University |
| issn | 0048-7449 2240-2683 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj-art-2ecaf44b3b5d4be88f33bf0cc617e61b2025-01-14T02:30:59ZengPAGEPress PublicationsReumatismo0048-74492240-26832025-01-0110.4081/reumatismo.2025.1718Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilastChiara Rizzo0https://orcid.org/0000-0003-4838-5854Silvia Grazzini1https://orcid.org/0000-0001-6541-2469Edoardo Conticini2https://orcid.org/0000-0002-3974-6606Hector Chinoy3https://orcid.org/0000-0001-6492-1288Roberto D’Alessandro4Federica Camarda5https://orcid.org/0000-0002-2548-0659Luca Cantarini6Bruno Frediani7Giuliana Guggino8https://orcid.org/0000-0003-2479-6958Lidia La Barbera9https://orcid.org/0009-0005-4208-5828Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of PalermoRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of SienaRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of SienaDepartment of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford; Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of ManchesterRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of SienaRheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of PalermoRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of SienaRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of SienaRheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of PalermoRheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo Objective. Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases that primarily affect striated muscles; skin, joints, and lungs may be involved with different degrees of severity. Traditional treatment relies on high-dose glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs. Methods. A growing amount of evidence is demonstrating the potential role of novel treatments in the management of IIM. We report our experience with Janus kinase inhibitors (JAKi) in these conditions and review the current evidence for the use of small molecules in real-life clinical practice. Results. A total of 41 papers were retrieved from PubMed, 37 papers concerning IIM and JAKi, and 4 papers concerning IIM and apremilast. Conclusions. An overall good efficacy was evidenced in IIM-associated skin lesions, including rash, ulcers, and calcinosis. If present, muscle and joint involvement demonstrated a good response to therapy, while it was not possible to draw any conclusion about dysphagia. No life-threatening adverse events were reported. https://www.reumatismo.org/reuma/article/view/1718Idiopathic inflammatory myopathiesmyositistreatmentJAK inhibitorsapremilasttsDMARDs |
| spellingShingle | Chiara Rizzo Silvia Grazzini Edoardo Conticini Hector Chinoy Roberto D’Alessandro Federica Camarda Luca Cantarini Bruno Frediani Giuliana Guggino Lidia La Barbera Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast Reumatismo Idiopathic inflammatory myopathies myositis treatment JAK inhibitors apremilast tsDMARDs |
| title | Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast |
| title_full | Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast |
| title_fullStr | Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast |
| title_full_unstemmed | Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast |
| title_short | Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast |
| title_sort | small molecules in idiopathic inflammatory myopathies a systematic review and a multicenter case series about janus kinase inhibitors and apremilast |
| topic | Idiopathic inflammatory myopathies myositis treatment JAK inhibitors apremilast tsDMARDs |
| url | https://www.reumatismo.org/reuma/article/view/1718 |
| work_keys_str_mv | AT chiararizzo smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT silviagrazzini smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT edoardoconticini smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT hectorchinoy smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT robertodalessandro smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT federicacamarda smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT lucacantarini smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT brunofrediani smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT giulianaguggino smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast AT lidialabarbera smallmoleculesinidiopathicinflammatorymyopathiesasystematicreviewandamulticentercaseseriesaboutjanuskinaseinhibitorsandapremilast |